Results 221 to 230 of about 232,812 (303)

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series

Blood Cancer Journal
Murali Janakiram, Lawrence Liu, Scott Goldsmith, Azra Borogovac, Sarah Lee, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Myo Htut   +8 more
doaj   +1 more source

Mandibular Plasmacytoma as the Initial Manifestation of Non-secretory Multiple Myeloma: A Rare Diagnostic Challenge. [PDF]

Cureus
Kr AK, Das S.
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections. [PDF]

Cancer Med
Zhu F, Wang H.
europepmc   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

Cancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang, Chenfei Zhao, Jingru Shi, Shiwei Liu, Yi Chen, Jujuan Wang, Zhengxu Sun, Sanmei Wang, Lei Fan, Jin Fan, Xiaoyan Qu   +10 more
wiley   +1 more source

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

Blood Cancer Journal
Ross S. Firestone, Anish K. Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H. Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn R. Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph O. Deasy, Saad Z. Usmani, Malin Hultcrantz   +19 more
doaj   +1 more source

An Uncommon Twist: Intussusception as a Rare Manifestation of Extramedullary Myeloma. [PDF]

Case Rep Surg
E Q, A EM, W D, P DG, D K.
europepmc   +1 more source

Voice Fundamental Frequency Variation and Statin Therapy

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Statins are considered a first‐line treatment for dyslipidaemia, being the most frequently prescribed medicine worldwide. However, statin therapy has been associated with several adverse effects, including statin‐associated myopathy, which may manifest with symptoms such as myalgia, muscle stiffness, and cramps.
Luca Francesco Parata, Paola Andreozzi, Lydia Thaleia Tzigkie, Marco de Vincentiis, Diletta Angeletti, Massimo Fusconi   +5 more
wiley   +1 more source